103565-40-8

Usage

Uses

Used in Pharmaceutical Applications:
Methyl 3-(4-aminomethylphenyl)propanoate(HCl) is utilized as an active pharmaceutical ingredient for the development of medications. Its unique structure and potential pharmacological effects make it a valuable component in drug discovery and formulation processes.
Used in Research Applications:
In the research industry, methyl 3-(4-aminomethylphenyl)propanoate(HCl) serves as a key compound in chemical libraries for drug discovery. Its presence in these libraries facilitates the exploration of its potential therapeutic properties and applications in various disease conditions.
Used in Medicinal Formulation:
Methyl 3-(4-aminomethylphenyl)propanoate(HCl) is employed as a key component in the formulation of medications, leveraging its stability and solubility to improve the efficacy and bioavailability of the final product.
Used in Chemical Libraries for Drug Discovery:
Methyl 3-(4-aminomethylphenyl)propanoate(HCl) is used as a reference compound in chemical libraries, where it contributes to the identification of new drug candidates and the advancement of pharmaceutical research.

Upstream product

• 325470-45-9 methyl 3-[4-(hydroxyiminomethyl)phenyl]acrylate 
• 104566-34-9 4-aminomethyl-cinnamic acid 

Downstream Products

• 132691-45-3 3-[4-[(tert.Butyloxycarbonylamino)methyl]phenyl]propionic acid 
• 132691-44-2 methyl 4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]benzenepropanoate 
• 191871-68-8 (R)-N₅-[Amino(nitroimino)methyl]-N₂-(diphenylacetyl)-N-[[4-[2-(methoxycarbonyl)ethyl]-phenyl]methyl]-ornithinamide 

Relevant academic research and scientific papers

Tryptase inhibitors

Compounds of formula (I) in which M, B1, B2, B3, B4, B5, B6, A1, A2, A3, A4, A5, A6, K1 and K2 have the meanings as indicated in the description, are novel effective tryptase inhibitors.

PYRROLIDINE DERIVATIVES AS TRYPTASE INHIBITORS

Compounds of a certain formula 1 in which M, B1, B2, R2, K1 and K2 have the meanings indicated in the description are novel effective tryptase inhibitors.

Tryptase inhibitors

A compound of formula I in which M, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, B5, B6, K1, and K2 are defined herein and are novel effective tryptase-inhibitors.

Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

NPY-antagonistic compounds of the formula STR1 Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate;(B) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-[bis(4-chlorphenyl)acetyl]-argininamide-trifluoracetate;(C) (R)-N-[[4-Aminocarbonylaminomethyl)phenyl]methyl]-N 2-(diphenylacetyl)-argininamide-trifluoracetate;(D) (R)-N 2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate;(E) (R,S)-N 5-(Aminoiminomethyl)-N 2-(diphenylacetyl)-N-[(4-hy-droxyphenyl)methyl]-N 5-methyl-ornithinamide-hydrochloride; (F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N 2-(diphenyl-acetyl)-argininamide-diacetate;(G) (R)-N. sup. 2-(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-phenyl]methyl]-argininamide-bis-(trifluoroacetate); and,(H) (R)-N. sup.2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate.

Cyclic imino derivatives and pharmaceutical compositions containing them

The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.